<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04890418</url>
  </required_header>
  <id_info>
    <org_study_id>2019/05JUL/303</org_study_id>
    <nct_id>NCT04890418</nct_id>
  </id_info>
  <brief_title>Risk Factors and Prevention of Severe Pain Upon Cessation of a Peripheral Nerve Block</brief_title>
  <acronym>PRPK</acronym>
  <official_title>Risk Factors and Prevention of Severe Pain Upon Cessation of a Peripheral Nerve Block. A Prospective Randomized Study in Ambulatory Patients Undergoing Upper Limb Bone Surgery Under Single Shot Axillary Plexus Block</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Risk factors and Prevention of severe Pain upon cessation of a peripheral nerve block. A&#xD;
      prospective randomized study in ambulatory patients undergoing upper limb bone surgery under&#xD;
      single shot axillary plexus block.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pain in the course of upper limb bone surgery is a major source of discomfort for patients&#xD;
      during postoperative time.&#xD;
&#xD;
      Severe post-operative pain is a risk factor for chronic pain. Use of a well-known molecule,&#xD;
      regularly used in anesthesiology. Prospective double-blind study on 120 patients. Pain&#xD;
      rebound upon awakening of the axillary plexus during upper limb bone surgery is a frequent&#xD;
      phenomenon in post-operative follow-up of patients.&#xD;
&#xD;
      The anti-hyperalgesic properties of ketamine could be a benefit against this effect.&#xD;
&#xD;
      No studies have combined intravenous ketamine with localoregional anesthesia to reduce pain&#xD;
      upon its release.&#xD;
&#xD;
      This may improve patients' post-operative comfort. The patients will be randomized in 2&#xD;
      groups and allocated to receive (slow intravenous injection) either 0.3 mg/kg intravenous&#xD;
      ketamine diluted into 10mL saline or 10 mL 0.9% saline after the realization of PNB, before&#xD;
      tourniquet set up and beginning of surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>The local pharmacy department is in charge of unmasking the drug.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>incidence of severe postoperative rebound pain</measure>
    <time_frame>from surgery to 30 days post operation</time_frame>
    <description>Rebound pain after PNB is defined as a Numerical rating Scale of 7 or more.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To measure the impact of ketamine on the level of &quot;rebound pain&quot; in patients with central sensitivity using the Numerical Rating Scale</measure>
    <time_frame>from surgery to 30 days postoperatively</time_frame>
    <description>Central sensitivity analyzed by a questionnaire and by Numerical Rating Scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>Study drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.3 mg/kg intravenous ketamine diluted into 10mL saline after the realization of peripheral nerve block (PNB), before tourniquet set up and beginning of surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>10 mL 0.9% saline after the realization of PNB, before tourniquet set up and beginning of surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketalar, 5 mg/mL Injectable Solution</intervention_name>
    <description>The patients will receive (slow intravenous injection) 0.3 mg/kg intravenous ketamine diluted by the pharmacy department into 10mL saline after the realization of PNB but before tourniquet set up and before start of surgery.</description>
    <arm_group_label>Study drug</arm_group_label>
    <other_name>Active comparator</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The patients will receive 10 mL of 0.9% saline. This injection is also performed after the realization of PNB but before tourniquet set up and before start of surgery.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo comparator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  any ambulatory upper limb bone surgery carried out under axillary PNB&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refusal to participate&#xD;
&#xD;
          -  Contraindication to the use of ketamine&#xD;
&#xD;
          -  Contraindication to regular use of postoperative analgesics like non-steroidal&#xD;
             anti-inflammatory drugs and paracetamol&#xD;
&#xD;
          -  Pregnant woman&#xD;
&#xD;
          -  Diabetic patient&#xD;
&#xD;
          -  Vascular patient&#xD;
&#xD;
          -  Cognitive disorders&#xD;
&#xD;
          -  Inability to answer perioperative questionnaires (language problem)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Patricia Lavand'homme</last_name>
    <phone>+3224741888</phone>
    <email>patricia.lavandhomme@uclouvain.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nassim Touil</last_name>
    <phone>+3224741888</phone>
    <email>nassim.touil@uclouvain.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia LAVAND'HOMME, PhD</last_name>
      <phone>3227641897</phone>
      <email>patricia.lavandhomme@uclouvain.be</email>
    </contact>
    <contact_backup>
      <last_name>Nassim TOUIL, MD</last_name>
      <phone>3227641888</phone>
      <email>nassim.touil@uclouvain.be</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 3, 2020</study_first_submitted>
  <study_first_submitted_qc>May 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2021</study_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

